A detailed history of Black Rock Inc. transactions in Cv Rx, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 875,753 shares of CVRX stock, worth $13.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
875,753
Previous 764,999 14.48%
Holding current value
$13.5 Million
Previous $13.9 Million 24.62%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$6.49 - $19.2 $718,793 - $2.13 Million
110,754 Added 14.48%
875,753 $10.5 Million
Q1 2024

May 10, 2024

SELL
$17.99 - $30.49 $691,445 - $1.17 Million
-38,435 Reduced 4.78%
764,999 $13.9 Million
Q4 2023

Feb 13, 2024

BUY
$11.67 - $33.01 $846,203 - $2.39 Million
72,511 Added 9.92%
803,434 $25.3 Million
Q3 2023

Nov 13, 2023

BUY
$13.56 - $18.47 $360,438 - $490,951
26,581 Added 3.77%
730,923 $11.1 Million
Q2 2023

Aug 11, 2023

BUY
$8.57 - $15.44 $5.51 Million - $9.93 Million
643,425 Added 1056.23%
704,342 $10.9 Million
Q1 2023

May 12, 2023

BUY
$7.08 - $19.4 $167,378 - $458,635
23,641 Added 63.42%
60,917 $567,000
Q4 2022

Feb 13, 2023

BUY
$8.94 - $18.35 $8,698 - $17,854
973 Added 2.68%
37,276 $684,000
Q3 2022

Nov 14, 2022

SELL
$6.12 - $9.5 $355,731 - $552,197
-58,126 Reduced 61.56%
36,303 $340,000
Q2 2022

Aug 12, 2022

SELL
$4.7 - $7.22 $1.43 Million - $2.2 Million
-305,216 Reduced 76.37%
94,429 $568,000
Q1 2022

May 12, 2022

BUY
$5.62 - $12.37 $23,789 - $52,362
4,233 Added 1.07%
399,645 $2.39 Million
Q4 2021

Feb 10, 2022

BUY
$10.65 - $18.61 $513,905 - $898,006
48,254 Added 13.9%
395,412 $4.84 Million
Q3 2021

Nov 09, 2021

BUY
$14.65 - $26.07 $5.09 Million - $9.05 Million
347,158 New
347,158 $5.74 Million

Others Institutions Holding CVRX

About CVRx, Inc.


  • Ticker CVRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 20,576,200
  • Market Cap $317M
  • Description
  • CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The co...
More about CVRX
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.